Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01087762 · ClinicalTrials.gov registry record · Phase 3
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 325
- Enrollment target
NCT01087762 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 325 participants.
The verdict
NCT01087762, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 325 participants
- Enrollment target
Study Summary
The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of Certolizumab Pegol (CZP) in subjects with active axial Spondyloarthritis (axial SpA).
Interventions
- OTHER Placebo
- BIOLOGICAL CZP 200 mg Q2W
- BIOLOGICAL CZP 400 mg Q4W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01087762
The ClinicalTrials.gov registry entry for NCT01087762 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01087762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01087762 about?
NCT01087762 is a clinical study titled "Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis". The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of Certolizumab Pegol (CZP) in subjects with active axial Spondyloarthritis (axial SpA).
What is the current status of trial NCT01087762?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 325 participants. The study started on 2010-03. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01087762?
The interventions under investigation include: Placebo (OTHER), CZP 200 mg Q2W (BIOLOGICAL), CZP 400 mg Q4W (BIOLOGICAL).
Who is sponsoring clinical trial NCT01087762?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.